Replies to post #150172 on Biotech Values

[DewDiligence]

But who in the 18-40 range is going to actually get the vaccine?

The new range is 18-49 (not 18-40); a lot of people in this range will want to be vaccinated against invasive pneumonia—e.g. healthcare workers, teachers, school administrators, and daycare workers.

I think it is only supposed to work for something like 5 years.

The FDA label for Prevnar 13 says that effectiveness in unknown when given less than five years after a vaccination of either Prevnar 13 or a competing product—i.e. such a repeat vaccination is likely to be superfluous. This is not the same thing as saying that Prenvar 13 provides only five years of immunity.

[DewDiligence]

PFE’s four biggest growth drivers, according to the company
(in no particular order):

• Eliquis
• Tofacitinib
• Prevanr 13 for adults (#msg-80291688)
• Growth of various products in emerging markets